Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
Corcept Therapeutics (NASDAQ: CORT) announced it will report its third quarter financial results on November 3, 2021, at 5:00 p.m. ET. A corporate update will accompany the financial results. The company is known for its drug Korlym®, the first FDA-approved treatment for Cushing's syndrome, and specializes in cortisol modulation for severe disorders. Interested participants can join the conference call by following the provided link or by dialing in. A replay of the call will be available until November 10, 2021.
- Corcept is a commercial-stage company focused on developing cortisol modulators for severe disorders.
- Korlym® is the first FDA-approved drug for Cushing's syndrome, showcasing the company's innovation.
- None.
MENLO PARK, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 3, 2021. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Conference Call Information
To participate, click the link below and enter your information. The link will become active 15 minutes prior to the scheduled start time.
Alternatively, you may dial 1-833-693-0540 from the United States or 1-661-407-1581 internationally approximately 15 minutes before the start of the call. The passcode will be 5763926.
A replay will be available through November 10, 2021, at 1-855-859-2056 from the United States and 1-404-537-3406 internationally. The passcode will be 5763926.
About Corcept Therapeutics Incorporated
Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s syndrome. Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol. The company owns extensive United States and foreign intellectual property covering the composition of its selective cortisol modulators and the use of cortisol modulators to treat a variety of serious disorders.
CONTACT:
Corcept Therapeutics
Investor Relations
ir@corcept.com
www.corcept.com
FAQ
When will Corcept Therapeutics report third quarter financial results?
What is the significance of Korlym® for Corcept Therapeutics?
How can I join the Corcept conference call on November 3, 2021?
Is there a replay available for the Corcept conference call?
